Bolodeoku J, Gbaa T, Morris K, Whitehead S. Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic. BJHR [Internet]. 2023 Dec. 17 [cited 2026 May 26];10(6):91-102. Available from: https://scholarpublishing.org/journals/index.php/BJHR/article/view/7376